Revolo Biotherapeutics Announces the Appointments of Marla S Persky and Glen Giovannetti to its Board of Directors forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Published: Dec 18, 2020 By Alex Keown
Cidara Therapeutics – Christopher Kurtz was named executive vice president of Technical Operations at Cidara Therapeutics. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Prior to joining Cidara, Kurtz served as head of commercial API manufacturing at Gilead Sciences. He previously served as vice president, for drug device industrialization at AbbVie, where he led product scale-up and industrialization projects for drug-device combinations. Prior to that, Kurtz held a number of leadership positions at various companies, including Monsanto, Nektar Therapeutics, Alza Corporation, Alexza and Novo Nordisk.
DGAP-News: Immun .
DGAP-News: Immune Regulation Limited: Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
vom 17.12.2020, 09:00 Uhr
Bild: pixabay.com
DGAP-News: Immune Regulation Limited / Key word(s): Personnel
Immune Regulation Limited: Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
17.12.2020 / 09:00
The issuer is solely responsible for the content of this announcement.
Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
(London UK, New Orleans US, 17 December, 2020) Immune Regulation Ltd, a US and UK based clinical stage biotechnology company announced today a series of appointments to build out the Board and leadership team that will work alongside Jonathan Rigby, Group CEO of Immune Regulation, in advancing the development of its fir
Immune Regulation Limited
Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
DGAP-News: Immune Regulation Limited / Key word(s): Personnel
Immune Regulation Limited: Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
17.12.2020 / 09:00
The issuer is solely responsible for the content of this announcement.
Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
(London UK, New Orleans US, 17 December, 2020) Immune Regulation Ltd, a US and UK based clinical stage biotechnology company announced today a series of appointments to build out the Board and leadership team that will work alongside Jonathan Rigby, Group CEO of Immune Regulation, in advancing the development of its first-in-class immune resetting therapies for autoimmune and allergic diseases.
Search jobs 17-Dec-2020 Immune Regulation Appoints New Chairman and Builds Out Senior Management Team with Standout Industry Professionals in the US
LONDON, UK and NEW ORLEANS, US, December 17, 2020 / B3C newswire / Immune Regulation Ltd, a US and UK based clinical stage biotechnology company announced today a series of appointments to build out the Board and leadership team that will work alongside Jonathan Rigby, Group CEO of Immune Regulation, in advancing the development of its first-in-class immune resetting therapies for autoimmune and allergic diseases.
Veteran biotech executive
Peter Greenleaf has been appointed
Chairman of the Board of Directors. Peter currently serves as the CEO and member of the Board of Directors of autoimmune therapeutics company Aurinia, (NASDAQ; AUPH / TSX; AUP). Previously, Peter served as the CEO of Cerecor Inc. (Nasdaq; CERC), the CEO and Chairman of Sucampo Pharmaceuticals Inc. (NASDAQ; SCMP),